SPONSOR
Sichuan Baili Pharmaceutical Co., Ltd.
Total Trials
12
Recruiting
12
Phases
Phase 1, Phase 2, Phase 1, Phase 2
Conditions studied: Breast CancerSolid TumorGastrointestinal TumorLocally Advanced or Metastatic Solid TumorCervical CancerEndometrial CancerGastrointestinal TumorsSolid TumorsRecurrent GliomaHer2-positive/Low-expression Urinary and Digestive Tract Tumors
NCT06609187 Phase 1
Recruiting
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Breast Cancer
NCT06042894 Phase 2
Recruiting
A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
Breast Cancer
NCT06954077 Phase 1
Recruiting
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Gastrointestinal Tumor
NCT05194982 Phase 1
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
Locally Advanced or Metastatic Solid Tumor
NCT05990803 Phase 2
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
Cervical Cancer
NCT07054567 Phase 2
Recruiting
A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Cervical Cancer
NCT07279428 Phase 1
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Gastrointestinal Tumors
NCT04794972 Phase 1
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Recurrent Glioma
NCT06031584 Phase 1, Phase 2
Recruiting
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
Her2-positive/Low-expression Urinary and Digestive Tract Tumors
NCT06006169 Phase 2
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Head and Neck Squamous Cell Carcinoma
NCT06503783 Phase 1
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
Breast Cancer
NCT07264816 Phase 2
Recruiting
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer